CD19 CAR circular RNA (circRNA) is designed to enable sustained expression of a chimeric antigen receptor (CAR) targeting human CD19, a B cell specific surface marker, through its covalently closed single-stranded RNA structure. In CAR-T therapy systems, when co-cultured with autologous T cells and activated through CD3/CD28, the CAR construct binds to CD19 on malignant B cells via its single-chain variable fragment (scFv), triggering T cell activation and cytotoxic killing through CD3ζsignaling and co-stimulatory domains. Unlike linear mRNA, the circular configuration of circRNA confers enhanced stability and resistance to exonuclease degradation, allowing prolonged CAR protein expression in transfected T cells.

• Used in CAR-T cell therapy.

• Self-circularized via the PIE strategy and includes a minimal scar sequence (Exon + Spacer).

• Designed with CVB3 IRES and codon optimization to enhance translational efficiency.

• Composed entirely of unmodified nucleotides.

• Chromatography purification ensures high quality and purity (Low nicked RNA).

• Carefully controlled processes to minimize batch-to-batch variation.